MYMD PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.52 USD | +12.00% |
|
+0.80% | -67.53% |
| Apr. 09 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
| Apr. 09 | Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
| 1st Jan change | Capi. | |
|---|---|---|
| -67.53% | 5.44M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -2.30% | 21.66B | |
| -18.35% | 20.77B | |
| -8.14% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- MYMD Stock
- News MyMD Pharmaceuticals, Inc.
- MyMD Pharmaceuticals : Pharma to Start Mid-Stage -1 Trial to Delay Aging
